tbuckley/cabot-search huggingface dataset:
Minors and Online Marijuana Accessibility—Navigating the Digital Backdoors
Authors: Kevin M. Simon
Journal: JAMA Pediatrics (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Revisions to Text in Results Section and Table 1
Journal: JAMA (2024)

Mikael Norman, MD, PhD; Boubou Hallberg, MD, PhD; Thomas Abrahamsson, MD, PhD; Lars J. Björklund, MD, PhD; Magnus Domellöf, MD, PhD; Aijaz Farooqi, MD, PhD; Cathrine Foyn Bruun, MD, PhD; Christian Gadsbøll, MD; Lena Hellström-Westas, MD, PhD; Fredrik Ingemansson, MD; Karin Källén, PhD; David Ley, MD, PhD; Karel Maršál, MD, PhD; Erik Normann, MD, PhD; Fredrik Serenius, MD, PhD; Olof Stephansson, MD, PhD; Lennart Stigson, MD; Petra Um-Bergström, MD; Stellan Håkansson, MD, PhD
Analysis of Breast Cancer Mortality in the US—1975 to 2019
Authors: Jennifer L. Caswell-Jin, Liyang P. Sun, Diego Munoz, Ying Lu, Yisheng Li, Hui Huang, John M. Hampton, Juhee Song, Jinani Jayasekera, Clyde Schechter, Oguzhan Alagoz, Natasha K. Stout, Amy Trentham-Dietz, Sandra J. Lee, Xuelin Huang, Jeanne S. Mandelblatt, Donald A. Berry, Allison W. Kurian, Sylvia K. Plevritis
Journal: JAMA (2024)

Breast cancer mortality in the US declined between 1975 and 2019. The association of changes in metastatic breast cancer treatment with improved breast cancer mortality is unclear.
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials
Authors: Mark Lebwohl, Richard B Warren, Howard Sofen, Shinichi Imafuku, Carle Paul, Jacek C Szepietowski, Lynda Spelman, Thierry Passeron, Eleni Vritzali, Andrew Napoli, Renata M Kisa, Alex Buck, Subhashis Banerjee, Diamant Thaçi, Andrew Blauvelt
Journal: British Journal of Dermatology (2024)

In the phase III POETYK PSO-1 and PSO-2 trials, deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, was well tolerated and efficacious over 1 year in patients with psoriasis.
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial
Authors: Jyoti Bajpai, Venkatesh Kapu, Sushmita Rath, Sravan Kumar, Anbarasan Sekar, Priyanka Patil, Altaf Siddiqui, Srikanth Anne, Akash Pawar, Sujay Srinivas, Prabhat Bhargava, Seema Gulia, Vanita Noronha, Amit Joshi, Kumar Prabhash, Shripad Banavali, Rajiv Sarin, Rajendra Badwe, Sudeep Gupta
Journal: The Lancet Oncology (2024)
The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa
Authors: Julio Rosenstock, Rattan Juneja, John M Beals, Julie S Moyers, Liza Ilag, Rory J McCrimmon
Journal: Endocrine Reviews (2024)

Abstract Basal insulin continues to be a vital part of therapy for many people with diabetes. First attempts to prolong the duration of insulin formulations were through the development of suspensions that required homogenization prior to injection. These insulins, which required once- or twice-daily injections, introduced wide variations in insulin exposure contributing to unpredictable effects on glycemia. Advances over the last 2 decades have resulted in long-acting, soluble basal insulin analogues with prolonged and less variable pharmacokinetic exposure, improving their efficacy and safety, notably by reducing nocturnal hypoglycemia. However, adherence and persistence with once-daily basal insulin treatment remains low for many reasons including hypoglycemia concerns and treatment burden. A soluble basal insulin with a longer and flatter exposure profile could reduce pharmacodynamic variability, potentially reducing hypoglycemia, have similar efficacy to once-daily basal insulins, simplify dosing regimens, and improve treatment adherence. Insulin icodec (Novo Nordisk) and insulin efsitora alfa (basal insulin Fc [BIF], Eli Lilly and Company) are 2 such insulins designed for once-weekly administration, which have the potential to provide a further advance in basal insulin replacement. Icodec and efsitora phase 2 clinical trials, as well as data from the phase 3 icodec program indicate that once-weekly insulins provide comparable glycemic control to once-daily analogues, with a similar risk of hypoglycemia. This manuscript details the technology used in the development of once-weekly basal insulins. It highlights the clinical rationale and potential benefits of these weekly insulins while also discussing the limitations and challenges these molecules could pose in clinical practice.
Calprotectin Impairs Platelet Survival in Patients With Primary Antiphospholipid Syndrome
Authors: Claire K. Hoy, Somanathapura K. NaveenKumar, Sherwin A. Navaz, Kavya Sugur, Srilakshmi Yalavarthi, Cyrus Sarosh, Tristin Smith, Katarina Kmetova, Emily Chong, Noah F. Peters, Christine E. Rysenga, Gary L. Norman, Gabriel Figueroa‐Parra, Dava Nelson, Jennifer Girard, Asra Z. Ahmed, Jordan K. Schaefer, Johann E. Gudjonsson, J. Michelle Kahlenberg, Jacqueline A. Madison, Jason S. Knight, Cynthia S. Crowson, Alí Duarte‐García, Yu Zuo
Journal: Arthritis & Rheumatology (2024)

While thrombosis and pregnancy loss are the best-known clinical features of antiphospholipid syndrome (APS), many patients also exhibit "extra-criteria" manifestations, such as thrombocytopenia. The mechanisms that drive APS thrombocytopenia are not completely understood, and no clinical biomarkers are available for predicting antiphospholipid antibody (aPL)-mediated thrombocytopenia. Calprotectin is a heterodimer of S100A8 and S100A9 that is abundant in the neutrophil cytoplasm and released upon proinflammatory neutrophil activation. Here, we sought to evaluate the presence, clinical associations, and potential mechanistic roles of circulating calprotectin in a cohort of primary APS and aPL-positive patients.
Comparison of PM2.5 Air Pollution Exposures and Health Effects Associations Using 11 Different Modeling Approaches in the Women’s Health Initiative Memory Study (WHIMS)
Authors: Melinda C. Power, Erin E. Bennett, Katie M. Lynch, James D. Stewart, Xiaohui Xu, Eun Sug Park, Richard L. Smith, Will Vizuete, Helene G. Margolis, Ramon Casanova, Robert Wallace, Lianne Sheppard, Qi Ying, Marc L. Serre, Adam A. Szpiro, Jiu-Chiuan Chen, Duanping Liao, Gregory A. Wellenius, Aaron van Donkelaar, Jeff D. Yanosky, Eric Whitsel
Journal: Environmental Health Perspectives (2024)

Background: Many approaches to quantifying air pollution exposures have been developed. However, the impact of choice of approach on air pollution estimates and health-effects associations remains unclear. Objectives: Our objective is to compare particulate matter with aerodynamic diameter ≤2.5μm (PM2.5) concentrations and resulting health effects associations using multiple estimation approaches previously used in epidemiologic analyses. Methods: We assigned annual PM2.5 exposure estimates from 1999 to 2004 derived from 11 different approaches to Women’s Health Initiative Memory Study (WHIMS) participant addresses within the contiguous US. Approaches included geostatistical interpolation approaches, land-use regression or spatiotemporal models, satellite-derived approaches, air dispersion and chemical transport models, and hybrid models. We used descriptive statistics and plots to assess relative and absolute agreement among exposure estimates and examined the impact of approach on associations between PM2.5 and death due to natural causes, cardiovascular disease (CVD) mortality, and incident CVD events, adjusting for individual-level covariates and climate-based region. Results: With a few exceptions, relative agreement of approach-specific PM2.5 exposure estimates was high for PM2.5 concentrations across the contiguous US. Agreement among approach-specific exposure estimates was stronger near PM2.5 monitors, in certain regions of the country, and in 2004 vs. 1999. Collectively, our results suggest but do not quantify lower agreement at local spatial scales for PM2.5. There was no evidence of large differences in health effects associations with PM2.5 among estimation approaches in analyses adjusted for climate region. Conclusions: Different estimation approaches produced similar spatial patterns of PM2.5 concentrations across the contiguous US and in areas with dense monitoring data, and PM2.5-health effects associations were similar among estimation approaches. PM2.5 estimates and PM2.5-health effects associations may differ more in samples drawn from smaller areas or areas without substantial monitoring data, or in analyses with finer adjustment for participant location. Our results can inform decisions about PM2.5 estimation approach in epidemiologic studies, as investigators balance concerns about bias, efficiency, and resource allocation. Future work is needed to understand whether these conclusions also apply in the context of other air pollutants of interest. https://doi.org/10.1289/EHP12995
Contralateral second dose improves antibody responses to a 2-dose mRNA vaccination regimen
Authors: Sedigheh Fazli, Archana Thomas, Abram E. Estrada, Hiro A.P. Ross, David Xthona Lee, Steven Kazmierczak, Mark K. Slifka, David Montefiori, William B. Messer, Marcel E. Curlin
Journal: Journal of Clinical Investigation (2024)

BACKGROUND. Vaccination is typically administered without regard to site of prior vaccination but this factor may substantially impact downstream immune responses.
Intravenous maintenance fluid therapy in acutely and critically ill children: state of the evidence
Authors: David W Brossier, Isabelle Goyer, Sascha C A T Verbruggen, Corinne Jotterand Chaparro, Shancy Rooze, Luise V Marino, Luregn J Schlapbach, Lyvonne N Tume, Frederic V Valla
Journal: The Lancet Child & Adolescent Health (2024)
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010–19: an analysis of data from a consortium of prospective cohort studies
Authors: Rachel Sacks-Davis, Daniela K van Santen, Anders Boyd, Jim Young, Ashleigh Stewart, Joseph S Doyle, Andri Rauch, Catrina Mugglin, Marina Klein, Marc van der Valk, Colette Smit, Inmaculada Jarrin, Juan Berenguer, Karine Lacombe, Maria-Bernarda Requena, Linda Wittkop, Olivier Leleux, Fabrice Bonnet, Dominique Salmon, Gail V Matthews, Rebecca Guy, Natasha K Martin, Tim Spelman, Maria Prins, Mark Stoove, Margaret Hellard, Margaret E Hellard, Rachel Sacks-Davis, Daniela K van Santen, Ashleigh Stewart, Tianhui Ke, Yanqin Zhang, Mark Stoove, Rebecca Guy, Alisa Pedrana, Jason Asselin, Joshua Dawe, Anna Wilkinson, Anders Boyd, Colette Smit, Marc van der Valk, Janke Schinkel, Linda Wittkop, Dominique Salmon, Philippe Sogni, Laure Esterle, Camille Gilbert, Laurence Merchadou, Stephanie Gillet, Coralie Khan, Fabrice Bonnet, Olivier Leleux, Fabien Le Marec, Adelaide Perrier, Gail Matthews, Ineke Shaw, Marianne Martinello, Tanya Applegate, Joanne Carson, Joseph S Doyle, Brendan Harney, Melissa Bryant, Inmaculada Jarrin Vera, Juan Berenguer, Belen Alejos, Jeffrey V Lazarus, Cristina Moreno, Rebecca Izquierdo, Marta Rava, Marina Klein, Shouao Wang, Jessica Lumia, Costa Pexos, Hansi Peiris, Sahar Saeed, Erica Moodie, Jim Young, Neora Pick, Brian Conway, Mark Hull, Alex Wong, John Gill, Lisa Barrett, Jeff Cohen, Joseph Cox, Pierre Cote, Shariq Haider, Danielle Rouleau, Marie-Louise Vachon, Anita Rachlis, Roger Sandre, Sharon Walmsley, Aida Sadr, Curtis Cooper, Steve Sanche, Andri Rauch, Catrina Mugglin, Luisa Salazar-Viscaya, Katharina Kusejko, Maria Prins, Kris Hage, Karine Lacombe, Maria-Bernada Requena, Pierre-Marie Girard, Matthieu Brucker, Jean-Paul Vincensini
Journal: The Lancet HIV (2024)
Broadening the Environmental Lens to Include Social and Structural Determinants of Women’s Health Disparities
Authors: Melissa M. Smarr, Megan Avakian, Adeline R. Lopez, Brenda Onyango, Sara Amolegbe, Abee Boyles, Suzanne E. Fenton, Quaker E. Harmon, Bill Jirles, Denise Lasko, Rosemary Moody, John Schelp, Vicki Sutherland, Laura Thomas, Carmen J. Williams, Darlene Dixon
Journal: Environmental Health Perspectives (2024)

Due to the physical, metabolic, and hormonal changes before, during, and after pregnancy, women—defined here as people assigned female at birth—are particularly susceptible to environmental insults. Racism, a driving force of social determinants of health, exacerbates this susceptibility by affecting exposure to both chemical and nonchemical stressors to create women's health disparities.
Glucocorticoid receptor-dependent therapeutic efficacy of tauroursodeoxycholic acid in preclinical models of spinocerebellar ataxia type 3
Authors: Sara Duarte-Silva, Jorge Diogo Da Silva, Daniela Monteiro-Fernandes, Marta Daniela Costa, Andreia Neves-Carvalho, Mafalda Raposo, Carina Soares-Cunha, Joana S. Correia, Gonçalo Nogueira-Goncalves, Henrique S. Fernandes, Stephanie Oliveira, Ana Rita Ferreira-Fernandes, Fernando Rodrigues, Joana Pereira-Sousa, Daniela Vilasboas-Campos, Sara Guerreiro, Jonas Campos, Liliana Meireles-Costa, Cecilia M.P. Rodrigues, Stephanie Cabantous, Sergio F. Sousa, Manuela Lima, Andreia Teixeira-Castro, Patricia Maciel
Journal: Journal of Clinical Investigation (2024)

Spinocerebellar ataxia type 3 (SCA3) is an adult-onset neurodegenerative disease caused by a polyglutamine expansion in the ataxin-3 (ATXN3) gene. No effective treatment is available for this disorder, other than symptom-directed approaches. Bile acids have shown therapeutic efficacy in neurodegenerative disease models. Here, we pinpointed tauroursodeoxycholic acid (TUDCA) as an efficient therapeutic, improving the motor and neuropathological phenotype of SCA3 nematode and mouse models. Surprisingly, transcriptomic and functional in vivo data showed that TUDCA acts in neuronal tissue through the glucocorticoid receptor (GR), but independently of its canonical receptor, the FXR. TUDCA was predicted to bind to the GR, similarly to corticosteroid molecules. GR levels were decreased in disease-affected brain regions, likely due to increased protein degradation as a consequence of ATXN3 dysfunction, being restored by TUDCA treatment. Analysis of a SCA3 clinical cohort showed intriguing correlations between the peripheral expression of GR and the predicted age at disease onset, in pre-symptomatic subjects, and of FKBP5 expression with disease progression, suggesting this pathway as a potential source of biomarkers for future study. We have established a novel in vivo mechanism for the neuroprotective effects of TUDCA in SCA3, and propose this readily available drug for clinical trials in SCA3 patients.
APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease
Authors: Somenath Datta, Brett M. Antonio, Nathan H. Zahler, Jonathan W. Theile, Doug Krafte, Hengtao Zhang, Paul B. Rosenberg, Alec B. Chaves, Deborah M. Muoio, Guofang Zhang, Daniel Silas, Guojie Li, Karen Soldano, Sarah Nystrom, Davis Ferreira, Sara E. Miller, James R. Bain, Michael J. Muehlbauer, Olga Ilkayeva, Thomas C. Becker, Hans-Ewald Hohmeier, Christopher B. Newgard, Opeyemi A. Olabisi
Journal: Journal of Clinical Investigation (2024)

Two coding variants of apolipoprotein L1 (APOL1) called G1 and G2 explain much of the excess risk of kidney disease in African Americans. While various cytotoxic phenotypes have been reported in experimental models, the proximal mechanism by which G1 and G2 cause kidney disease is poorly understood. Here, we leveraged three experimental models and a recently reported small molecule blocker of APOL1 protein, VX-147, to identify the upstream mechanism of G1-induced cytotoxicity. In HEK293 cells, we demonstrated that G1-mediated Na+ import/K+ efflux triggered activation of G protein-coupled receptor (GPCR)-IP3-mediated calcium release from the endoplasmic reticulum (ER), impaired mitochondrial ATP production, and impaired translation, which were all reversed by VX-147. In human podocyte-like epithelial cells (HUPEC), we demonstrated that G1 caused cytotoxicity that was again reversible by VX-147. Finally, in podocytes isolated from APOL1 G1 transgenic mice, we showed that Interferon gamma (IFNγ)-mediated induction of G1 caused K+ efflux, activation of GPCR-IP3 signaling, and inhibition of translation, podocyte injury, and proteinuria, all reversed by VX-147. Together, these results establish APOL1-mediated Na+/K+ transport as the proximal driver of APOL1-mediated kidney disease.
Chemo-photothermal nanoplatform with diselenide as the key for ferroptosis in colorectal cancer
Authors: Kaili Deng, Hailong Tian, Tingting Zhang, Yajie Gao, Edouard C. Nice, Canhua Huang, Na Xie, Guoliang Ye, Yuping Zhou
Journal: Journal of Controlled Release (2024)
Integration of Pan-Cancer Single-Cell and Spatial Transcriptomics Reveals Stromal Cell Features and Therapeutic Targets in Tumor Microenvironment
Authors: Yanhua Du, Jintong Shi, Jiaxin Wang, Zhenzhen Xun, Zhuo Yu, Hongxiang Sun, Rujuan Bao, Junke Zheng, Zhigang Li, Youqiong Ye
Journal: Cancer Research (2023)

Abstract Stromal cells are physiologically essential components of the tumor microenvironment (TME) that mediates tumor development and therapeutic resistance. Development of a logical and unified system for stromal cell type identification and characterization of corresponding functional properties could help design antitumor strategies that target stromal cells. Here, we performed a pan-cancer analysis of 214,972 nonimmune stromal cells using single-cell RNA sequencing from 258 patients across 16 cancer types and analyzed spatial transcriptomics from 16 patients across seven cancer types, including six patients receiving anti–PD-1 treatment. This analysis uncovered distinct features of 39 stromal subsets across cancer types, including various functional modules, spatial locations, and clinical and therapeutic relevance. Tumor-associated PGF+ endothelial tip cells with elevated epithelial–mesenchymal transition features were enriched in immune-depleted TME and associated with poor prognosis. Fibrogenic and vascular pericytes (PC) derived from FABP4+ progenitors were two distinct tumor-associated PC subpopulations that strongly interacted with PGF+ tips, resulting in excess extracellular matrix (ECM) abundance and dysfunctional vasculature. Importantly, ECM-related cancer-associated fibroblasts enriched at the tumor boundary acted as a barrier to exclude immune cells, interacted with malignant cells to promote tumor progression, and regulated exhausted CD8+ T cells via immune checkpoint ligand–receptors (e.g., LGALS9/TIM-3) to promote immune escape. In addition, an interactive web-based tool (http://www.scpanstroma.yelab.site/) was developed for accessing, visualizing, and analyzing stromal data. Taken together, this study provides a systematic view of the highly heterogeneous stromal populations across cancer types and suggests future avenues for designing therapies to overcome the tumor-promoting functions of stromal cells. Significance: Comprehensive characterization of tumor-associated nonimmune stromal cells provides a robust resource for dissecting tumor microenvironment complexity and guiding stroma-targeted therapy development across multiple human cancer types.
Augmentation of scleral glycolysis promotes myopia through histone lactylation
Authors: Xiaolei Lin, Yi Lei, Miaozhen Pan, Changxi Hu, Bintao Xie, Wenjing Wu, Jianzhong Su, Yating Li, Yuhan Tan, Xiaohuan Wei, Zhengbo Xue, Ruiyan Xu, Mengqi Di, Hanyu Deng, Shengcong Liu, Xingxing Yang, Jia Qu, Wei Chen, Xiangtian Zhou, Fei Zhao
Journal: Cell Metabolism (2024)
Haplotype-specific assembly of shattered chromosomes in esophageal adenocarcinomas
Authors: Jannat Ijaz, Edward Harry, Keiran Raine, Andrew Menzies, Kathryn Beal, Michael A. Quail, Sonia Zumalave, Hyunchul Jung, Tim H.H. Coorens, Andrew R.J. Lawson, Daniel Leongamornlert, Hayley E. Francies, Mathew J. Garnett, Zemin Ning, Peter J. Campbell
Journal: Cell Genomics (2024)

The epigenetic landscape of cancer is regulated by many factors, but primarily it derives from the underlying genome sequence. Chromothripsis is a catastrophic localized genome shattering event that drives, and often initiates, cancer evolution. We characterized five esophageal adenocarcinoma organoids with chromothripsis using long-read sequencing and transcriptome and epigenome profiling. Complex structural variation and subclonal variants meant that haplotype-aware de novo methods were required to generate contiguous cancer genome assemblies. Chromosomes were assembled separately and scaffolded using haplotype-resolved Hi-C reads, producing accurate assemblies even with up to 900 structural rearrangements. There were widespread differences between the chromothriptic and wild-type copies of chromosomes in topologically associated domains, chromatin accessibility, histone modifications, and gene expression. Differential epigenome peaks were most enriched within 10 kb of chromothriptic structural variants. Alterations in transcriptome and higher-order chromosome organization frequently occurred near differential epigenetic marks. Overall, chromothripsis reshapes gene regulation, causing coordinated changes in epigenetic landscape, transcription, and chromosome conformation.
Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells
Authors: Jenny Sprooten, Isaure Vanmeerbeek, Angeliki Datsi, Jannes Govaerts, Stefan Naulaerts, Raquel S. Laureano, Daniel M. Borràs, Anna Calvet, Vanshika Malviya, Marc Kuballa, Jörg Felsberg, Michael C. Sabel, Marion Rapp, Christiane Knobbe-Thomsen, Peng Liu, Liwei Zhao, Oliver Kepp, Louis Boon, Sabine Tejpar, Jannie Borst, Guido Kroemer, Susan Schlenner, Steven De Vleeschouwer, Rüdiger V. Sorg, Abhishek D. Garg
Journal: Cell Reports Medicine (2024)

Current immunotherapies provide limited benefits against T cell-depleted tumors, calling for therapeutic innovation. Using multi-omics integration of cancer patient data, we predict a type I interferon (IFN) response